Needham analyst Mike Matson initiated coverage of ShockWave Medical with a Buy rating and $240 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SWAV:
- ShockWave Medical management to meet with Piper Sandler
- ShockWave Medical announces U.S. launch of new peripheral IVL catheter
- Neovasc shareholders approve acquisition by ShockWave Medical
- ShockWave Medical sees FY23 revenue $660M-$680M, consensus $658.58M
- ShockWave Medical price target raised to $252 from $247 at Canaccord